文献速递脑血管病

他汀类药物使用与脑出血后卒中复发风险的关联

Association of Statin Use With Risk of Stroke Recurrence After Intracerebral Hemorrhage.
PubMed 文献 · Neurology · 2023-08-30

基于丹麦卒中登记处2003年1月至2021年12月首次脑出血且存活超过30天的50岁及以上患者,采用巢式病例对照分析,发现他汀暴露与任何卒中(aOR 0.88)和缺血性卒中(aOR 0.79)风险降低相关,与复发性脑出血风险无关(aOR 1.05),需随机试验确认。

要点

  • 他汀暴露与任何卒中风险降低相关(aOR 0.88, 95%CI 0.78-0.99)。
  • 他汀暴露与缺血性卒中风险降低相关(aOR 0.79, 95%CI 0.67-0.92)。
  • 他汀暴露与复发性脑出血风险无关(aOR 1.05, 95%CI 0.88-1.24)。

核心结论

  • 他汀暴露与复发性脑出血风险增加无关,但与任何卒中风险降低相关,主要归因于缺血性卒中风险降低。
  • 需要在随机试验中确认这些发现。

研究设计与样本

  • 利用丹麦卒中登记处,纳入2003年1月至2021年12月首次发生脑出血、年龄50岁及以上且存活超过30天的患者,随访至2022年8月。
  • 在队列内进行3项巢式病例对照分析,分别针对任何卒中、缺血性卒中和复发性脑出血,对照按年龄、性别、距首次脑出血时间和既往缺血性卒中史匹配。
  • 任何卒中组1959例匹配7400名对照;缺血性卒中组1073例匹配4035名对照;复发性脑出血组984例匹配3755名对照。

主要发现

  • 任何卒中组他汀暴露比例为病例38.6% vs 对照41.1%,aOR 0.88(95%CI 0.78-0.99)。
  • 缺血性卒中组他汀暴露比例为病例39.8% vs 对照41.8%,aOR 0.79(95%CI 0.67-0.92)。
  • 复发性脑出血组他汀暴露比例为病例39.1% vs 对照40.8%,aOR 1.05(95%CI 0.88-1.24)。

关键数值与推荐

  • 任何卒中组:女性45.3%,平均年龄72.6岁(SD 9.7)。
  • 缺血性卒中组:女性42.0%,平均年龄72.4岁(SD 10.0)。
  • 复发性脑出血组:女性48.7%,平均年龄72.7岁(SD 9.2)。
  • 该研究提供Class III证据:脑出血患者使用他汀与任何卒中和缺血性卒中风险降低相关,与复发性脑出血风险增加无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要在随机试验中确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Survivors of spontaneous intracerebral hemorrhage (ICH) may have indications for statin therapy. The effect of statins on the risk of subsequent hemorrhagic and ischemic stroke (IS) in this setting is uncertain. We sought to determine the risk of any stroke (ischemic stroke, IS or recurrent ICH), IS, and recurrent ICH associated with statin use among ICH survivors. METHODS: Using the Danish Stroke Registry, we identified all patients admitted to a hospital in Denmark (population 5.8 million) with a first-ever ICH between January 2003 and December 2021 who were aged 50 years or older and survived >30 days. Patients were followed up until August 2022. Within this cohort, we conducted 3 nested case-control analyses for any stroke, IS, and recurrent ICH. We matched controls for age, sex, time since first-ever ICH, and history of prior IS. The primary exposure was statin use before or on the date of subsequent stroke or the equivalent date in matched controls. Using conditional logistic regression, we calculated adjusted odds ratios (aORs) and corresponding 95% confidence intervals (CIs) for any stroke, IS, and recurrent ICH associated with statin exposure. RESULTS: We identified 1,959 patients with any stroke (women 45.3%; mean [SD] age, 72.6 [9.7] years) who were matched to 7,400 controls; 1,073 patients with IS (women 42.0%; mean [SD] age, 72.4 [10.0] years) who were matched to 4,035 controls and 984 patients with recurrent ICH (women 48.7%; mean [SD] age, 72.7 [9.2] years) who were matched to 3,755 controls. Statin exposure was associated with a lower risk of both any stroke (cases 38.6%, controls 41.1%; aOR 0.88; 95% CI 0.78-0.99) and IS (cases 39.8%, controls 41.8%, aOR 0.79; 95% CI 0.67-0.92), but was not associated with recurrent ICH risk (cases 39.1%, controls 40.8%, aOR 1.05; 95% CI 0.88-1.24). DISCUSSION: Exposure to statins was not associated with an increased risk of recurrent ICH but was associated with a lower risk of any stroke, largely due to a lower risk of IS. Confirmation of these findings in randomized trials is needed. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that statin use in patients with ICH is associated with a lower risk of any stroke and IS and not with increased risk of recurrent ICH.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Gaist D, García Rodríguez LA, Hallas J, et al. Association of Statin Use With Risk of Stroke Recurrence After Intracerebral Hemorrhage. Neurology. 2023. PMID: 37648526. doi:10.1212/WNL.0000000000207792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。